We have developed a heterobifunctional all-small molecule PROTAC (PROteolysis TArgeting Chimera) capable of inducing proteasomal degradation of the androgen receptor. This cellpermeable PROTAC consists of a non-steroidal androgen receptor ligand (SARM) and the MDM2 ligand known as nutlin, connected by a PEG-based linker. The SARM-nutlin PROTAC recruits the androgen receptor to MDM2, which functions as an E3 ubiquitin ligase. This leads to the ubiquitination of the androgen receptor, and its subsequent degradation by the proteasome. Upon treatment of HeLa cells with 10 μM PROTAC for 7h, we were able to observe a decrease in androgen receptor levels. This degradation is proteasome dependent, as it is mitigated in cells pretreated with 10 μM epoxomicin, a specific protease inhibitor. These results have implications for the potential study and treatment of various cancers with increased androgen receptor levels.
The PROTAC strategy employs the protein degradation machinery of the cell: the ubiquitinproteasome pathway. Proteins removed via this pathway are targeted for degradation by the attachment of a polyubiquitin chain, leading to their recognition and subsequent degradation by the 26S proteasome. 8 The selectivity of this process is governed by the recognition of the targeted protein by an E3 ubiquitin ligase associated with an E2 conjugating enzyme coupled to ubiquitin. Upon binding of the target protein, ubiquitin is transferred to an accessible lysine residue, thus labeling the protein for proteasome-mediated degradation. The PROTAC strategy seeks to exploit this degradation pathway by promoting the nonnatural ubiquitination of a targeted protein. The PROTAC molecule consists of a ligand, which binds an E3 ubiquitin ligase, connected by a linker to another ligand that binds the target protein. The association between a protein and an E3 ligase, as induced by a PROTAC molecule, will lead to the transfer of ubiquitin and degradation of the targeted protein ( Figure 1) .
We have previously shown that a heterobifunctional PROTAC can actively induce selective intracellular protein degradation. 6, 7 However, this first generation of PROTAC molecules contained a peptide-based ligand for the E3 ligase, which limited its permeability. The subsequent addition of a polyarginine chain mimicking the HIV viral TAT 9 protein overcame cell permeability issues in the next generation of PROTACs. While significant biological activity was seen using these early PROTACs, the synthesis, purification and stability issues associated with their high molecular weight and vulnerable peptide bonds, limited their broad applicability. We are now able to report an all-small molecule-based PROTAC that can efficiently induce intracellular protein degradation while bypassing the drawbacks associated with the peptide moiety in the previous generation of compounds.
The PROTAC molecule itself contains three distinct portions: a ligand for binding to the target protein, a ligand for binding to an E3 ligase, and a linker joining these two ligands. For this proof of concept all-small molecule PROTAC we chose to target the androgen receptor (AR), as we have had success degrading this protein previously using a peptidebased PROTAC. 7 In addition, AR is an attractive target because it has been shown to promote the growth of prostate tumor cells, while the inhibition of AR has been shown to repress tumor cell growth. 10 Moreover, there are a variety of known small molecule ligands for AR. For this PROTAC we opted to use a selective androgen receptor modulator (SARM), which binds AR with a K i of 4 nM. 11 We chose to recruit targeted the androgen receptor via this class of PROTACs to the E3 ligase MDM2, which is a 90 kDa protein whose natural substrate is p53. 12 Recently a new class of imidazoline derivatives that bind MDM2 has been identified. 13 These compounds, called nutlins, have been shown to disrupt the binding of MDM2 and its natural ligand p53 with IC 50 values in the nano-to micromolar range, leading to the stabilization of p53 protein levels. For use in our all-small molecule PROTAC, a nutlin derivative (racemic nutlin-3, MDM2 binding affinity: enantiomer a IC 50 =13.6 μM, enantiomer b IC 50 =0.09 μM) 13 was prepared utilizing an efficient one-pot condensation/oxidation strategy (Scheme 1). 14,15 The triaryl imidazoline substrate was easily accessed via condensation of diamine 2 with substituted benzaldehyde 1. The intermediate 2,4,5 triarylimidazolidine was oxidized in situ by addition of NBS to the reaction mixture to provide the cis-imidazoline 3 in good yield. 5 and 6 were combined in the presence of base to give ester 10, which was then treated under standard hydrogenolysis conditions to give amine 8. Subsequent urea formation was performed as previously reported, to produce the acid 4. 16 A short soluble PEG linker was chosen to bridge the two terminal protein ligands; synthesis of this linker is shown in Scheme 2. 17 First, azido alcohol 9 was treated with sodium iodoacetate in the presence of base to give acid 10, which was subsequently treated with 4-aminophenol hydrochloride under standard peptide coupling conditions (EDCI, HOBt) to afford phenol 11 in good yield. Having developed an efficient strategy for the preparation of nutlin derivatives, the synthesis of the SARM-nutlin PROTAC 14 proceeded smoothly as shown in Scheme 3. 18 Epoxide 12 was prepared as previously reported using D-proline as a chiral auxiliary. 11 Epoxide opening of 12 with phenol 11 was followed by a Staudinger reduction of the azide to provide amine 13. Coupling of 13 to the acid 4 afforded a diastereomeric mixture of the SARM-nutlin PROTAC, 14.
The SARM-nutlin PROTAC was tested for induced intracellular protein degradation using HeLa (human cervical carcinoma) cells transiently expressing the androgen receptor. Cells were treated with 10 μM PROTAC or vehicle alone, and incubated at 37°C. Cell lysates were prepared after 7h, separated by SDS-PAGE, and transferred to nitrocellulose membrane. Western blots were assessed using an anti-AR antibody to determine AR protein levels. 19 We were able to observe a reproducible decrease in total AR in cells treated with the PROTAC as compared to the vehicle-treated cells ( Figure 2 ). To verify that androgen receptor degradation induced by the PROTAC is proteasome dependent, we pre-treated cells with the specific proteasome inhibitor epoxomicin, at 10 μM concentration for 1h. 20 These cells were then treated with either vehicle or 10 μM PROTAC. Again, cells were incubated for 7h, harvested, and analyzed by Western blot with anti-AR antibody. 21 These results, shown in Figure 2 , clearly show that PROTAC-mediated degradation is proteasome dependent, as AR degradation is inhibited in the presence of epoxomicin. A slight accumulation of AR is noticeable in epoxomicin-treated cells, reflecting the loss of normal protein turnover due to proteasome inhibition.
In summary, we report here the first synthesis of an all-small molecule PROTAC. We have shown this compound to be both cell permeable and capable of promoting selective interaction between an E3 ligase and a target protein, leading to specific intracellular protein degradation. We have also shown this degradation to be proteasome dependent. These results are an important step in the pursuit of small molecule PROTAC libraries, which could potentially provide new insights into a number of important biological pathways through loss-of-function phenotypes. In addition, these results lend support for potential PROTAC-based therapeutic approaches in the treatment of various diseases.
(9). Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. Proc. Natl. To a solution of azido alcohol 9 (780 mg, 4.454 mmol) in DMF (4.5 mL) at 0 °C was added NaH (60%, 178 mg, 4.454 mmol). After stirring at 0°C for 30 min, sodium iodoacetate (926 mg, 4.454 mmol) was added to the mixture. The reaction mixture was stirred at rt for 32 h and quenched with 1N-HCl in an ice bath. The mixture was extracted three times with ethyl acetate. The extracts were washed with saturated NaCl solution, dried over Na 2 SO 4 , filtered, and concentrated. The concentrate was purified by flash column chromatography (1:99 methanol-dichloromethane initially, grading to 1:9 methanoldichloromethane) to provide 860 mg (83%) of acid 10. 1 3 OH in EtOAc), R f 0.12 (CAM). Phenol 11. To a solution of acid 10 (250 mg, 1.072 mmol) and 4-aminophenol hydrochloride (156 mg, 1.072 mmol) in CH 2 Cl 2 (4 mL) at rt were added HOBt (174 mg, 1.286 mmol) and DIPEA (0.47 mL, 2.680 mmol). The mixture was cooled to 0 °C and EDCI (226 mg, 1.179 mmol) was added to the mixture. The reaction mixture was allowed to room temperature and further stirred at rt for 18 h. The resulting mixture was quenched with H 2 O in an ice bath. The mixture was extracted three times with ethyl acetate. The extracts were washed with saturated NaCl solution, dried over Na 2 SO 4 , filtered, and concentrated. The concentrate was purified by flash column chromatography (1:99 methanol-dichloromethane initially, grading to 1:9 methanol-dichloromethane) to afford 302 mg (87%) of phenol 11. 1 PROTAC mechanism of action: The heterobifunctional PROTAC molecule contains two binding motifs: one recruits an E3 ligase, and another recruits the target protein. Following binding to the PROTAC, the E3 ligase catalyzes the synthesis of a polyubiquitin chain on the target, leading to its recognition by the 26S proteasome, and subsequent target protein degradation. The SARM-nutlin PROTAC effectively degrades the androgen receptor (AR) in vivo. HeLa cells transiently expressing AR were treated with either vehicle, 10 μM PROTAC 14, or pretreated with 10 μM epoxomicin and then 10 μM PROTAC, for 7h. Cells were then lysed and separated by SDS-PAGE. The total level of AR was detected by Western blotting using an anti-AR antibody (top). As a loading control, the same membrane was probed using an anti-α-tubulin antibody (bottom). 
